HER-2-targeted Boron Neutron Capture Therapy Using an Antibody-conjugated Boron Nitride Nanotube/β-1,3-glucan Complex

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2023 Jul 27

PMID 37496630

Authors

Keita Yamana

Riku Kawasaki

Kousuke Kondo

Hidetoshi Hirano

Shogo Kawamura

Yu Sanada

Kaori Bando

Anri Tabata

Hideki Azuma

Takushi Takata

Yoshinori Sakurai

Hiroki Tanaka

Tomoki Kodama

Seiji Kawamoto

Takeshi Nagasaki

Atsushi Ikeda

Affiliations

Soon will be listed here.

Abstract

The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.

Citing Articles

Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges.

Ahmad F Biomater Res. 2025; 29:0145.

PMID: 40008112 PMC: 11850861. DOI: 10.34133/bmr.0145.

Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness.

Punshon L, Fabbrizi M, Phoenix B, Green S, Parsons J Cells. 2025; 13(24.

PMID: 39768156 PMC: 11674336. DOI: 10.3390/cells13242065.

Recent progress of nano-drugs in neutron capture therapy.

Zhou Y, Cheng K, Liu B, Cao Y, Fan J, Liu Z Theranostics. 2024; 14(8):3193-3212.

PMID: 38855185 PMC: 11155403. DOI: 10.7150/thno.95034.

References

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Nahta R, Esteva F . Trastuzumab: triumphs and tribulations. Oncogene. 2007; 26(25):3637-43. DOI: 10.1038/sj.onc.1210379. View

Ciofani G, Danti S, Genchi G, Mazzolai B, Mattoli V . Boron nitride nanotubes: biocompatibility and potential spill-over in nanomedicine. Small. 2013; 9(9-10):1672-85. DOI: 10.1002/smll.201201315. View

Kawamura S, Kawasaki R, Hino S, Yamana K, Okuno M, Eto T . Formulation of water-dispersible hydrophobic compound nanocomplexes with polypeptides a supramolecular approach using a high-speed vibration milling technique. RSC Adv. 2022; 12(49):32012-32019. PMC: 9641674. DOI: 10.1039/d2ra06054j. View

Best R, LaPointe N, Azarenko O, Miller H, Genualdi C, Chih S . Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol Appl Pharmacol. 2021; 421:115534. DOI: 10.1016/j.taap.2021.115534. View

Barth R, SOLOWAY A, Fairchild R, Brugger R . Boron neutron capture therapy for cancer. Realities and prospects. Cancer. 1992; 70(12):2995-3007. DOI: 10.1002/1097-0142(19921215)70:12<2995::aid-cncr2820701243>3.0.co;2-#. View

Ito K, Hamamichi S, Asano M, Hori Y, Matsui J, Iwata M . Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models. Cancer Sci. 2015; 107(1):60-7. PMC: 4724823. DOI: 10.1111/cas.12841. View

Ikeda A, Hayashi K, Konishi T, Kikuchi J . Solubilization and debundling of purified single-walled carbon nanotubes using solubilizing agents in an aqueous solution by high-speed vibration milling technique. Chem Commun (Camb). 2004; (11):1334-5. DOI: 10.1039/b402042a. View

Nakamura H, Koganei H, Miyoshi T, Sakurai Y, Ono K, Suzuki M . Antitumor effect of boron nitride nanotubes in combination with thermal neutron irradiation on BNCT. Bioorg Med Chem Lett. 2014; 25(2):172-4. DOI: 10.1016/j.bmcl.2014.12.005. View

10.

Salama A, Pusey C . Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol. 2006; 2(4):221-30. DOI: 10.1038/ncpneph0133. View

11.

Nelson A, Dhimolea E, Reichert J . Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9(10):767-74. DOI: 10.1038/nrd3229. View

12.

Yumoto T, Satake S, Hino S, Sugikawa K, Kawasaki R, Ikeda A . Improved water solubility and photodynamic activity of hydroxy-modified porphyrins by complexation with cyclodextrin. Org Biomol Chem. 2020; 18(34):6702-6709. DOI: 10.1039/d0ob01379j. View

13.

Ricart A . Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011; 17(20):6417-27. DOI: 10.1158/1078-0432.CCR-11-0486. View

14.

Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

15.

Beck A, Goetsch L, Dumontet C, Corvaia N . Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16(5):315-337. DOI: 10.1038/nrd.2016.268. View

16.

Kawasaki R, Hirano H, Yamana K, Isozaki H, Kawamura S, Sanada Y . Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy. Nanomedicine. 2023; 49:102659. DOI: 10.1016/j.nano.2023.102659. View

17.

Barth R, Mi P, Yang W . Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018; 38(1):35. PMC: 6006782. DOI: 10.1186/s40880-018-0299-7. View

18.

Kawasaki R, Yamana K, Shimada R, Sugikawa K, Ikeda A . Water Solubilization and Thermal Stimuli-Triggered Release of Porphyrin Derivatives Using Thermoresponsive Polysaccharide Hydroxypropyl Cellulose for Mitochondria-Targeted Photodynamic Therapy. ACS Omega. 2021; 6(4):3209-3217. PMC: 7860233. DOI: 10.1021/acsomega.0c05647. View

19.

Doronina S, Mendelsohn B, Bovee T, Cerveny C, Alley S, Meyer D . Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006; 17(1):114-24. DOI: 10.1021/bc0502917. View

20.

Yamana K, Kawasaki R, Sanada Y, Tabata A, Bando K, Yoshikawa K . Tumor-targeting hyaluronic acid/fluorescent carborane complex for boron neutron capture therapy. Biochem Biophys Res Commun. 2021; 559:210-216. DOI: 10.1016/j.bbrc.2021.04.037. View